Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
Clinical trial NCT03694236 · RECRUITING
Trial details
- NCT number
- NCT03694236
- Sponsor
- Yonsei University
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-12
- Primary completion
- 2027-05-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.